Core Viewpoint - Wuhan Binhui Biotechnology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, aiming to commercialize innovative cancer immunotherapy through oncolytic virus therapy [1][3]. Company Overview - Binhui Biotechnology is focused on the discovery, development, and commercialization of innovative cancer immunotherapies, specifically oncolytic virus therapies that aim to meet urgent clinical needs globally [3]. - The company is led by Dr. Liu Binlei, who has over 30 years of expertise in tumor immunology and oncolytic virology, and was a core member of the team that developed the first FDA-approved oncolytic virus drug, IMLYGIC [3]. Product Pipeline - Binhui has established a diverse pipeline with five products at various development stages, including the core product BS001, an oncolytic virus candidate based on HSV-2 [4]. - BS001 selectively replicates in tumor cells, triggering oncolysis and activating systemic immune responses, and is being studied for various solid tumor indications, including melanoma and colorectal cancer [4]. Clinical Development - BS001 is the first oncolytic virus candidate based on HSV-2 to reach the clinical stage and enter Phase III trials, with the potential to be the first approved therapy of its kind globally [5]. - The drug has received breakthrough therapy designation and orphan drug status from the FDA for treating advanced melanoma and glioblastoma, and has shown promising early clinical trial results [5]. Financial Performance - For the fiscal years ending June 30, 2023, and 2024, Binhui reported revenues of 0.981 million and 1.725 million RMB, respectively, with significant losses of approximately 110.1 million and 113.1 million RMB [6][7]. - The company has incurred substantial research and development expenses, amounting to 106.8 million RMB in 2023, reflecting its focus on advancing its clinical programs [7].
滨会生物递表港交所 已将BS001推进至中国黑色素瘤III期临床试验
Zhi Tong Cai Jing·2025-09-30 13:21